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The Impact of PRAMI Trial on Interventional Practice in ST-Segment Elevation Myocardial 
Infarction in a University Hospital 
 
Momina F Yazdani, Shabnam Rashid, Chris Sawh, Julian Gunn, James Richardson 
  
Background: 
Randomized-control trials, notably PRAMI, demonstrated that immediate percutaneous coronary 
intervention (PCI) in significantly stenosed, non-infarct vessels in ST elevation MI (STEMI) patients 
reduces adverse outcomes. However, the impact on clinical practice is unknown. 
 
Aim 
To investigate if the number of immediate non-infarct PCIs has changed after publication of PRAMI, 
and the impact on mortality. 
 
Methods: 
STEMI patients with multivessel disease (>50% stenosis) presenting 1 year before and 1 year after 
PRAMI were included. Exclusion criteria was equivalent to PRAMI. Patients were divided into 
immediate PCI or staged PCI group (within 12 weeks). Data was analysed using SPSS Statistics® 
Version 22. 
 
Results: 
1472 STEMI patients were analysed. 426 had multivessel disease with 202 in Pre-PRAMI group and 
224 in Post-PRAMI group. Of these 19 patients (9.4%) had immediate angioplasty in the Pre-PRAMI 
group, compared to 28 (12.5%) in the Post-PRAMI group (Odds Ratio 1.37, 95% CI,0.74-2.54, 
p=0.309).In the Pre-PRAMI group, 21 patients (10.4%) had staged PCI compared to 30 (13.4%) in the 
post-PRAMI group, Odds Ratio (1.33, 95% CI, 0.74-2.41). 
 
Pre-PRAMI, 16% of patients who had immediate PCI died over a mean of 27 months. The 30 day, 6 
month and 1 year mortality was 5%, 10% and 10% respectively. Post-PRAMI, 14% of patients who 
had immediate PCI died over a mean of 15 months. The 30 day, 6 month and 1 year mortality was 
11%, 11% and 14 % respectively. 
 
In those who had staged PCI no deaths were seen either before or after PRAMI publication. Overall, 
immediate PCI (15%) was associated with significantly higher mortality than staged PCI cohort (0%) 
(Log rank test p=0.005). 
 
Conclusions: 
1 year after publication, our center demonstrated a trend to increased immediate PCI to non-infarct 
vessel, but not the widespread adoption of routine multi vessel PPCI suggested by PRAMI. 
Immediate PCI of non-culprit vessels was associated with increased mortality, which likely reflects 
the higher underlying risk of cases judged to require multi vessel PCI, however increased early 
hazard cannot be discounted. Further larger randomized controlled trials are needed before 
immediate multivessel PCI is routinely practiced. 
